

Breaking the Chain in Therapy of Mucormycosis

Haren Pandya*, Hiren Patel, Hitesh Dewan, Bijal Bhavsar, Urvi Shah, Surya Singh

Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, Dharmsinh Desai University, Nadiad, India.

Abstract

Background: Mucormycosis is a life-threatening fungal disease that occurs in immunocompromised patients. However, treating the disease without reaching the depth of its pathogenesis wavers one from establishing the effectiveness of said treatment. We present two cases of patients with maxillary mucormycosis with diabetes mellitus as comorbidity, where we studied the role of iron as a benefactor to the progression of the disease and were treated with aggressive surgical management and antifungal drug. **Methods:** In both cases, patients were put on empirical antibiotics. Incisional biopsy was performed. Glycemic control was achieved and later surgical intervention in the form of sequestromy (Case 1) and partial maxillectomy (Case 2) was performed. **Results:** For both cases, healing occurred with neovascularization. **Conclusion:** High mortality rates despite current regimen of mucormycosis remain unacceptable. Focusing on eliminating predisposing factors seems more feasible than the foreboding nephrotoxic effect of antifungal therapy with its added resistance. This article aims to highlight the fact that therapy to control ketoacids and iron chelating agents, along with antifungal, should be used to augment the results.

Keywords: Diabetes mellitus, Immunocompromised host, Iron, Mucormycosis.

INTRODUCTION

Mucormycosis is a lethal infection caused by a saprophytic fungus that belongs to the order Mucorales, family Mucoraceae, and class Zygomycetes the genera of Mucorales that are *Rhizopus oryzae*, *Absidia*, *Rhizomucor*, and *Mucor*. It manifests in a rhinocerebral, pulmonary, gastrointestinal, cutaneous, or disseminated form. It's association with comorbidities like uncontrolled diabetes mellitus is acidotic and occurs in patients with hematologic malignant disease like leukemia or patients receiving immunosuppressive therapy. Symptoms involving the oral and craniofacial tissues account for about 60% of all cases.^[1] In uncontrolled diabetes mellitus, the most common signs within the head-and-neck region are maxillary and orbital cellulitis.^[2] Intraorally, the hard palate is mostly affected because of its proximity to the infection of the nasal fossa. If left untreated, this condition will cause severe comorbidity with craniofacial spread and death.^[1] It poses a diagnostic and therapeutic dilemma for people who are not acquainted with its clinical presentations.

We describe our clinical experience with two cases of mucormycosis of the maxilla related to uncontrolled diabetes mellitus managed at our center. The series of cases was reported with subsequent aims:

1. To highlight the clinical presentation of mucormycosis
2. To emphasize the requirement for early diagnosis, prompt, and aggressive surgical management

3. To form awareness that reduction of the predisposing factors results in hampering the proliferation of fungus.

Case 1

A 50-year-old female patient reported to maxillofacial department with pain in upper right back teeth region for 2 months. The patient was unaware of her medical condition. The patient gave a history of removal of faulty prosthesis and extraction of mobile teeth in upper arch before 3 months.

On clinical examination, facial symmetry was present and paresthesia was evident over right cheek. Whitish-yellow exposed bone observed in the right maxillary arch extending from 13 to 16 region of approximately 3 cm × 2 cm in size (Figure 1). Palatal defect in midline along with exposed bone was seen. No sign of nasal regurgitation. Halitosis presents with the absence of pus discharge. Alveolar segment 13–16, tender on palpation with no segmental mobility.

Address for correspondence: Haren Pandya,
15, Shanti Sadan Society, Opposite Mangal Baug, Near Parimal Garden,
Ahmedabad - 380 006, India.
Email: drharenpandya@gmail.com

Received: 22 Jun, 2021; **Accepted:** 19 Jul, 2021; **Published:** 28 Aug, 2021

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Pandya H, Patel H, Dewan H, Bhavsar B, Shah U, Singh S. Breaking the Chain in Therapy of Mucormycosis. J Res Adv Dent 2021;12(5):258-262.

Access this article online

Website:
www.jrad.co.in

DOI:
<https://doi.org/10.53064/jrad.2021.12.5.66>

An orthopantomogram (OPG) showed atrophic maxilla and mandible. However, computed tomography scan showed diffuse heterogeneous and sclerotic appearance of the right maxillary sinus. Bone lysis and erosion involving right lateral half of anterior portion of hard palate and alveolar arch. Routine biochemical investigations showed elevated random blood sugar (RBS) levels 377 mg/dl and HbA1c-10.7.

The patient was hospitalized and treated by cefotaxime 2000 mg/day, metronidazole 1500 mg/day, and insulin actrapid. A provisional diagnosis of maxillary osteomyelitis was made. Incisional biopsy of affected area was done under local anesthesia and sent for microbiological and histopathological examination (HPE). HPE report revealed broad, septate/pauci septate ribbon-like Mucorales hyphae.

The patient underwent surgery for maxillary sequestrectomy with antral curettage and complete removal of necrotic tissue was done leaving fresh oozing bleeding margins at wound site and course of antifungals was started. Good post-operative healing was noted (Figure 2). The patient was kept for follow-up and obturator placement was done (Figure 3) after a month with no recurrence within 1 year follow-up.



Figure 1: Exposed maxillary bone



Figure 2: Post-operative healing after a month

Case 2

A 65-year-old male patient reported to maxillofacial department with pain in upper right back teeth region since a week. The patient was hypertensive and diabetic for 5 years and was on medication for same with habit of bidi smoking 10–12 packet/day for 35 years.

On clinical examination, facial symmetry was present. Whitish-yellow exposed bone in anterior palate extending beyond midline covering right maxillary arch extending from 11 to 15 of approximately 3 cm × 3 cm in size (Figure 4). Sinus tract with purulent discharge was present in relation to (irt) 14,15 along with halitosis. Nasal regurgitation was absent. Alveolar segment irt 11–15 was tender on palpation. No segmental mobility was present.

OPG showed generalized horizontal bone loss. Computed tomography scan revealed mucosal thickening in bilateral maxillary, frontal, sphenoid, and ethmoid sinus. Routine biochemical investigations showed elevated RBS 402 mg/dl, HbA1c 8.2, and PP2BS 322mg/dl.

The patient was hospitalized and treated by cefotaxime 2000 mg/day, metronidazole 1500 mg/day, and insulin actrapid as well as mixtard. A provisional diagnosis of acute suppurative osteomyelitis of maxilla was made. Incisional biopsy of affected area was done under local anesthesia and



Figure 3: Obturator placement



Figure 4: Exposed palatal bone

sent for microbiological and HPE. HPE report showed broad, septate ribbon-like fungal hyphae. Uncontrolled diabetes and hypertension were managed before planning any surgical procedure.

Once the values were acceptable, the patient underwent for partial maxillectomy from 17 to 24 region with antral curettage and complete debridement was carried out, and the wound was left for healing with secondary intention (Figure 5). Course of antifungals was started. Improvement of healing and pus discharge was checked daily until better healing with neovascularization appeared. Then, the patient is kept on follow-up.



Figure 5: Specimen

DISCUSSION

Mucormycosis is a life-threatening disease which requires multifactorial approach. The ultimate outcome of mucormycosis along with other factors depends on ability to reverse the predisposing conditions. In aforementioned cases, prompt correction of hyperglycemia and acidemia, followed by surgery, was done. The stepwise approach taken up was starting patients on antibiotic regimen sans antifungal therapy which was later initiated after post-surgery as for socioeconomic reasons, the patient could not afford high end antifungal drugs. Meanwhile, predisposing factors were kept in line. Said predisposing factors which augment spread of mucormycosis include uncontrolled diabetes mellitus, raised serum iron levels. Role of these factors in disease progression is explained subsequently.

Role of diabetic ketoacidosis

Fungi grow better in an environment of increased glucose which causes excessive glycosylation of proteins such as ferritin and transferrin as well as low pH impairs their ability to chelate iron. Phagocytic effect of neutrophils is affected by low serum pH (Figure 6).^[1-4] Martin showed that in diabetic patients, polymorphonuclear leukocytes impair due to glycolytic process and produce less lactic acid than those from normal individuals. This reduction in bactericidal activity of the leukocyte is reversed by insulin.^[5] Angeliki *et al.* suggested that *Rhizopus* changes physiological killing mechanisms of macrophages and established prolonged intracellular dormancy through melanin-induced phagosome maturation arrest. The




Figure 6: Role of diabetes in mucormycosis

inhibition of *Rhizopus* growth inside macrophages is a central host defense mechanism that depends on nutritional immunity through iron starvation.^[6]

Other factors which lead to the decreased resistance to infection in diabetes are as follows:

1. Reduced number of antibodies
2. Lowered state of general cellular nutrition
3. Decreased activity of complement system
4. Reduced levels of properdin
5. Vascular insufficiency.^[5]

The role of iron in cell growth of fungus

Iron has necessary role within the life cycle of Mucorales and its utilization from the host could be a critical pathogenetic mechanism of mucormycosis. Iron is necessary for DNA synthesis and for oxygen transporters in mitochondria which activates the cyclin/cyclin-dependent kinase complexes, thus regulating the progression from the G1-phase to the S-phase of the cell cycle. Fungus, entering the S-phase of the cell cycle, upregulates transferrin receptor-1 expression to get iron from the extracellular environment (Figure 7).^[7]

The cyclin-dependent kinase inhibitor p21CIP1/WAF1 increases when intracellular Fe³⁺ decreases, thus delaying or inhibiting transition to S-phase. Hence, Bcl-2 is downregulated and Bax levels are increased, conditions that activate caspase-3, caspase-8, and caspase-9 which lead to apoptosis and cell death. Serum and other biological fluids act as fungistatic for fungi but pathogens require 10⁻⁶–10⁻⁷ M iron for growth.^[7]

Iron uptake by mucormycosis pathogenesis

Iron is an important element for cell growth and development binds to host carrier proteins, such as transferrin, ferritin, and lactoferrin. This degradation avoids lethal effect of free iron. When exogenous iron is added, Mucorales particularly *R. oryzae* grows extensively in normal serum. Patients with

DKA have elevated levels of free iron in their serum which supports growth of *R. oryzae* at acidic pH (7.3–6.88) but not at alkaline pH (7.78–8.38) (Figure 7).^[8,9]

High-affinity iron permeases or low-molecular-weight iron chelators (siderophores) are used by fungi to obtain iron. The high-affinity iron permeases present in fungi contains redundant surface reductases that reduce ferric into the more soluble ferrous form. Three ferric reductases, six copper oxidases, and one high-affinity iron permease captures reduced ferrous iron. The gene encoding high-affinity iron permease (FTR1) is expressed by *R. oryzae* and inhibition of FTR1 gene expression by RNA-I, reduction of FTR1 copy number by gene disruption reduces the virulence of the mucor.^[10]

Rhizopus secretes rhizoferrin, a siderophore (low-molecular-weight iron chelators) forms rhizoferrin iron complex that supplies iron through a receptor-mediated, energy-dependent process. Through use of heme, fungi can obtain iron from the host. *Rhizopus* genome project revealed two homologues of the heme oxygenase which obtain iron from host hemoglobin. *R. oryzae* will facilitate intracellular heme uptake by the use of FTR1, then heme oxygenases acts intracellularly and releases ferrous iron.^[10,11]

Role of deferoxamine

Deferoxamine is used in patients with iron overload strips ferric iron from transferrin and attaches itself on the mold through an inducible receptor, and acts as xenosiderophore to *Rhizopus* by transporting it intracellular by an active reduction of the ferric form into the more soluble ferrous form (Figure 7).^[6,12,13]

The fungal proteins Fob1 and Fob2 act specifically as receptors for iron uptake from deferoxamine in patients with diabetic ketoacidosis, increases availability of free iron in the serum due to protonation of transferrin, are a critical pathogenetic event in the development of mucormycosis.^[6,14]




Figure 7: Role of iron in mucormycosis

Deferiprone (DFP) and deferasirox (DFX) do not act as xenosiderophores as the fungal iron uptake systems are incapable of detaching iron from them. DFP and DFX might form more stable chemical structures with iron that are not destabilized in the presence of fungal enzymes or siderophores due to inadequate molecular access, as they are smaller molecules than DFO, or higher affinity for iron.^[7,15]

Host–pathogen interactions

Mucormycosis infections are characterized by extensive angioinvasion that results in vessel thrombosis and subsequent tissue necrosis which prevent delivery of leukocytes and antifungal agents to the foci of infection. Hematogenous dissemination to other target organs leads to angioinvasion. *Rhizopus* adheres to the extracellular matrix laminin and type IV collagen and invades cells by induced endocytosis. Endocytosed *Rhizopus* damages endothelial cells. GRP-78 is a receptor which helps mucorales for penetration and it damages endothelial cells.^[10,16-18]

The fungal ligand binds to GRP78 during invasion of the endothelium belongs to the spore coating (CotH) protein family. Interaction between Mucorales CotH and endothelial cell GRP78 receptor and the ability of CotH mediate invasive disease. More copies of CotH in Mucorales result invasive disease.^[10,14,19]

Rhizotoxin, a type of toxin produced directly from Mucorales, mediates the interaction between the pathogen and the host.^[10,14]

Pathogenesis driven diagnosis and treatment

Curbing a lethal disease such as mucormycosis has been subject of interest for years. Reaching its core pathogenesis and acting on it can bring about change in treatment algorithm of current times. New antifungal agents with activity against Mucorales and passive immunization such as iron acquisition through high-affinity iron permease can be proven effective against its immunopathogenesis. CotH proteins and Mucorales-specific T cells may act as a potential diagnostic test for mucormycosis in future.^[1,20] The article focuses on the significance of supplemental treatment in treating such life-threatening infections.

CONCLUSION

High mortality rates despite current regimen of mucormycosis remain unacceptable. Focusing on eliminating predisposing factors in this article seems more feasible than foreboding nephrotoxic effect of antifungal therapy with its added resistance. Mucorales already present in the wound can be stopped proliferating by altering the environment, favorable for their growth. This entails controlling the ketoacids (diabetic ketoacidosis) and iron uptake since Mucorales thrive on iron. Along with that, aggressive therapy with antifungals and surgical debridement would prove to be exponentially helpful in improving the outcome of an otherwise dreaded disease.

This article aims to highlight the fact that therapy to control ketoacids and iron chelating agents, along with antifungal, should be used to augment the results. Cases were treated at our place taking into consideration the above facts which lead to dramatically encouraging results in our cases.

REFERENCES

1. Anehosur V, Agrawal SM, Joshi VK, Anand J, Krisnamurthy K, Kumar N. Incidence and treatment protocol for maxillofacial fungal osteomyelitis: A 12-year study. *J Oral Maxillofac Surg* 2019;77:2285-91.
2. Pandey A, Bansal V, Asthana A, Trivedi V. Case report maxillary osteomyelitis by mucormycosis: Report of four cases. *Int J Infect Dis* 2011;15:e66-9.
3. Bala K, Chander J, Handa U, Punia R, Attri A. A prospective study of mucormycosis in north India: Experience from a tertiary care hospital. *Med Mycol* 2015;53:248-57.
4. Arani R, Shareef A, Khanam K. Mucormycotic osteomyelitis involving the maxilla: A rare case report and review of the literature. *Case Rep Infect Dis* 2019;2019:8459296.
5. Quintiliani R. A Study of Mucormycosis with Special Reference to its Pathogenesis. Boston: Dissertation Boston University; 1960. Available from: <http://www.open.bu.edu>. [Last accessed on 2021 Jul 22].
6. Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Sameh SM, *et al.* Iron restriction inside macrophages regulates pulmonary host defense against *Rhizopus* species. *Nat Commun* 2018;9:4683.
7. Symeonidis AS. The role of iron and iron chelators in zygomycosis. *Clin Microbiol Infect* 2009;15:26-32.
8. Spellberg B, Edwards J Jr., Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. *Clin Microbiol Rev* 2005;18:556-69.
9. Riley TT, Munzy CA, Swatlo E, Legendre DP. Breaking the mold: A review of mucormycosis and current pharmacological treatment options. *Ann Pharmacother* 2016;50:747-57.
10. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis. *Clin Infect Dis* 2012;54:S16-22.
11. Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. *Curr Opin Infect Dis* 2013;26:508-15.
12. Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: Perspectives from a maxillofacial surgeon. *Clin Microbiol Infect* 2009;15:98-102.
13. Francis JR, Villanueva P, Bryant P, Blyth CC. Mucormycosis in children: Review and recommendations for management. *J Pediatr Infect Dis Soc* 2017;7:1-6.
14. Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-the bitter and the sweet. *PLoS Pathog* 2017;13:1-9.
15. Dan M. Mucormycosis of the head and neck. *Curr Infect Dis Rep* 2011;13:123-31.
16. Doni BR, Thotappa LH, Peerapur BV, Hippargi SB. Sequence of oral manifestations in rhino-maxillary mucormycosis. *Indian J Dent Res* 2011;22:331-5.
17. Kumar N, Vande AV. Mucormycosis of maxilla following tooth extraction in immunocompetent patients: Reports and review. *J Clin Exp Dent* 2018;10:e300.
18. Reddy SS, Rakesh N, Chuahan P, Sharma S. Rhinocerebral mucormycosis among diabetic patients: An emerging trend. *Mycopathologia* 2015;180:389-96.
19. Danion F, Aguilar C, Catherinot E, Alanio A, Dewof S, Lortholary O, *et al.* Mucormycosis: New developments into a persistently devastating infection. *Semin Respir Crit Care Med* 2015;36:692-705.
20. Sipsas NV, Gamaletsou M, Kontoyiannis DP. Therapy of mucormycosis. *J Fungi* 2018;4:90.